Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCAP-XX Regulatory News (CPX)

Share Price Information for CAP-XX (CPX)

Share Price is delayed by 15 minutes
Get Live Data
0.265    -0.005 (-1.85%)
Bid:
0.25
Ask:
0.28
Spread: 0.03 (12.00%)
Market Cap: £15.36m
CPX Live PriceLast checked at - London Stock Exchange

Intraday CAP-XX Share Chart

Trading Update

7 May 2024 07:00

RNS Number : 3875N
CAP-XX Limited
07 May 2024
 

Dissemination of a Regulatory Announcement that contains inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.

 

7 May 2024

CAP-XX Limited

("CAP-XX" or the "Company")

Trading update

CAP-XX Limited, a world leader in the design and manufacture of supercapacitors and energy management systems, provides the following update.

Following the successful completion of the recent fundraise, the Board is pleased to announce that current trading on existing products remains strong, in line with management forecasts, and trial shipments of pre-samples of new product have recently commenced. Bookings and billings are 14% and 56% ahead respectively for the year to date compared to the comparative period in 2023, along with a current book to bill ratio of 1.12. The order backlog remains strong at close to US$1 million.

 

As previously stated, the proceeds from the fundraise are being used to improve the Company's financial position and provide working capital for investment. Key areas for investment include the continued expansion of the sales representative and distribution network, and working capital for the market introduction of the new DMH and SMD products. The vast bulk of the development costs of the latter has already been incurred, although some final commissioning of the DMH production line remains. An initial pre-series batch of fully functional DMH product is currently under lab evaluation and SMD testing remains on track. In addition, the Company expects to announce further patents during the next three months.

 

The Board considers that, apart from the final settlement of legal costs associated with the Maxwell/Tesla litigation, which it does not consider material, the only remaining payments for legal costs will be normal ongoing corporate legal expenses, including, for example, those associated with applications for patents.

 

In addition, the Company has implemented a comprehensive cost reduction program, which has delivered annualised operating cost savings in excess of US$0.5 million, and is expected to ensure that CAP-XX successfully overcomes its recent challenging phase.

 

The target for breakeven remains in the 2026 calendar year, assuming billings maintain their current growth trend. This is being supported by the recent investment in CAP-XX's international direct sales and marketing, the expansion of the distributor network, together with design wins and billings from our new product families, DMH and SMD, which will contribute in 2025 and 2026 respectively.

 

Following the conclusion of the financial year ending 30 June 2024, CAP-XX intends to provide a comprehensive update to investors on products and markets and corporate strategy at a Capital Markets seminar, which will be hosted on-line, details of which will be issued in due course.

 

Lars Stegmann, Chief Executive of CAP-XX, said "I'd like to thank our shareholders for their continued support. We look forward to the next exciting phase for the Company, as we prepare for our new product launches, supported by a strengthening sales and distribution team. We believe this has the potential to transform the commercial success of CAP-XX."

 

 

For further information contact:

CAP-XX Limited

Pat Elliott (Chairman) +61 (2) 9157 0000

Lars Stegmann (Chief Executive Officer)

 

Allenby Capital (Nominated Adviser and Joint Broker)

David Hart / Piers Shimwell (Corporate Finance)  +44 (0) 20 3328 5656

Tony Quirke / Stefano Aquilino (Sales and Corporate Broking)

 

Cavendish Securities plc (Joint Broker)

Neil McDonald / Pearl Kellie +44 (0) 13 1220 6939

 

Kreab (Financial PR)

Robert Speed +44 (0) 20 7074 1800

 

 

Notes to Editors:

CAP-XX (LSE: CPX) is a leader in the design and manufacture of thin, flat supercapacitors and energy management systems used in portable and small-scale electronic devices, and to an increasing extent, in larger applications such as automotive and renewable energy. The unique feature of CAP-XX supercapacitors is their very high power density and high energy storage capacity in a space-efficient prismatic package. These attributes are essential in power-hungry consumer and industrial electronics, and deliver similar benefits in automotive and other transportation applications. For more information about CAP-XX, visit www.cap-xx.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPUUCAUPCUAM
Date   Source Headline
31st Oct 20244:35 pmRNSProposed Fundraising
21st Oct 20249:57 amRNSUpdate re. final results and current trading
16th Oct 20247:00 amRNSContract Win
5th Sep 20247:00 amRNSTrading Update and Notice of Results
30th Aug 20245:00 pmRNSTotal Voting Rights
14th Aug 20247:12 amRNSGrant of options
6th Aug 20249:18 amRNSHolding(s) in Company
5th Aug 20247:00 amRNSExercise of warrants and total voting rights
29th Jul 20247:00 amRNSHolding(s) in Company
16th Jul 20247:00 amRNSMOU to establish technology partnership
18th Jun 20247:00 amRNSBoard Changes and Grant of Share Options
20th May 20247:00 amRNSHolding(s) in Company
13th May 20247:00 amRNSHolding(s) in Company
7th May 202410:10 amRNSHolding(s) in Company
7th May 20247:00 amRNSTrading Update
1st May 202411:08 amRNSHolding(s) in Company
30th Apr 20245:00 pmRNSTotal Voting Rights
25th Apr 20249:24 amRNSHolding(s) in Company
24th Apr 20245:04 pmRNSN05/24 - CAP-XX Limited - Restoration of trading
23rd Apr 20248:36 amRNSResult of General Meeting
8th Apr 20249:12 amRNSLitigation with Kyocera AVX settled
28th Mar 20245:00 pmRNSTotal Voting Rights
27th Mar 20248:22 amRNSSuspension of trading
27th Mar 20247:29 amRNSN04/24 - CAP-XX Limited - Suspension of trading
25th Mar 20247:00 amRNSResult of Retail Offer and Total Voting Rights
22nd Mar 20247:00 amRNSResult of Placing and Notice of General Meeting
21st Mar 20244:40 pmRNSREX Retail Offer
21st Mar 20244:35 pmRNSProposed Placing and Subscription to raise £2.0m
21st Mar 20249:00 amRNSLitigation Settlement Agreement with Tesla, Inc
19th Mar 202412:31 pmRNSHolding(s) in Company
18th Mar 20242:56 pmRNSHolding(s) in Company
15th Mar 202412:50 pmRNSHolding(s) in Company
15th Mar 20247:07 amRNSHolding(s) in Company
14th Mar 20247:00 amRNSUpdate on litigation
13th Mar 20247:00 amRNSCorporate Update
12th Mar 20247:00 amRNSRetirement of CFO
28th Feb 20247:00 amRNSUpdate on litigation and trading
19th Feb 20247:00 amRNSCessation of appeals process
1st Feb 20247:00 amRNSInterim Results
29th Jan 20247:00 amRNSUpdate on Patent Infringement
22nd Jan 202412:57 pmRNSChange of Joint Broker
10th Jan 20247:02 amRNSUpdate on IP and appeals process
29th Dec 20231:00 pmRNSTotal Voting Rights
21st Dec 20237:00 amRNSTrading Update
18th Dec 20237:00 amRNSUpdate on Patent Infringement
7th Dec 20237:00 amRNSCAP-XX finalises two new patents
5th Dec 20237:00 amRNSIssue of Shares and Director/PDMR Shareholdings
1st Dec 20237:00 amRNSUpdate re. R&D rebate and other matters
29th Nov 20237:00 amRNSHolding(s) in Company
22nd Nov 202311:29 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.